Hydralazine as Demethylating Agent in Breast Cancer

The objective of this study is to determine the MTD for hydrazaline added to standard neoadjuvant chemotherapy for operable breast cancer. Four dose levels of hydrazalline are planned: Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID Patients will be treated in cohorts of 3 and no patient may be treated at more that one dose level. Additional cohorts may not be initiated until toxicity has been fully evaluated in the current cohort of patients. The MTD is exceeded when a dose level produces a dose limiting toxicity (DLT) in at least two of the three patients in a cohort. Dose escalation will proceed by increasing the dose according to the following table. Number of Events/Number in Cohort Action 0/3 Proceed to next dose level 1/3 Accrue 3 more patients at the same dose 1/3 + 0/3 Proceed to next dose level 1/3 + 1/3 Stop: Previous dose level is MTD 1/3 + 2/3 Stop: Previous dose level is MTD 1/3 + 3/3 Stop: Previous dose level is MTD 2/3 Stop: Previous dose level is MTD 3/3 Stop: Previous dose level is MTD If the MTD has been exceeded by dose escalation and only one cohort with no observed toxicities was tested at the previous dose level, an additional cohort of 3 patients will be tested at the previous dose level. Thus, six patients must be treated at the dose declared the MTD. In the unlikely event that 150 mg/day of hydralazine, the starting dose, produces two or more DLTs, the daily dose of hydralazine will be reduced by 50mg to100 mg/day. If two or more toxicities are observed at this reduced dose level, the study will be stopped and the phase II study will not be performed. This phase I study will require between 9 to 24 patients. The cohort of six patients treated at the MTD will be used in the subsequent phase II trial. Definition of Dose Limiting Toxicities Because the study drug is not a cytotoxic agent, is being "added" to a toxic chemotherapy regimen in women likely to be normotensive, and because the drug has been evaluated in the cardiovascular literature with maximum clinical doses at 300 mg/d, we made the following decisions that deviate from classic "cytotoxic" agent schemes. The deviations are as follows: * Dose escalation beyond the "CLINNICALLY MAXIMAL" dose of 250 mg/d are not planned, and * The definition of a DLT will not adhere to the NCI CTC - designed for cytotoxic agents, but will rather be simply the tolerability of the drug by the patient as documented in the protocol and reproduced below: 1. Symptomatic hypotension, 2. Blood pressure recording of \< 90 mmHg systolic, or \<55 mgHg diastolic, 3. Other side effects deemed unacceptable either to the patient or the treating physician, and 4. Patient request/refusal to continue on study. Patients having to go off the drug will be considered as DLT events.